Prospective Comparison of Revolve™ and AuraGen 123 With AuraClens™ in Autologous Fat Grafting to the Breast

Sponsor
AuraGen Aesthetics LLC (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04906811
Collaborator
(none)
20
1
2
19.4
1

Study Details

Study Description

Brief Summary

The purpose of this study is to compare fat graft retention over time from lipoaspirate processed using two FDA-cleared devices: the Revolve System (K120902) and the AuraGen 1-2-3 with AuraClens Lipoaspirate Wash System (BK190433).

Condition or Disease Intervention/Treatment Phase
  • Device: AuraGen 1-2-3 with AuraClens system (BK190433)
  • Device: Revolve System (K120902)
N/A

Detailed Description

This is a single-center, prospective, randomized study enrolling patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. A total of 20 patients will be enrolled in the study. Ten patients will receive lipoaspirate processed with the Revolve and ten patients will have lipoaspirate processed with the AuraGen 1-2-3 with AuraClens.

Patients will be followed on post-procedure months 3, 6, and 12. Fat graft retention will be evaluated by photographic assessment by blinded reviewers, and 3D imaging. Patient satisfaction will be measured using the Breast-Q - Augmentation survey.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Prospective Comparison of the Revolve™ and AuraGen 1-2-3™ With AuraClens™ Systems in Processing of Lipoaspirate for Autologous Fat Grafting to the Breast
Actual Study Start Date :
May 20, 2021
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Fat grafting with the AuraGen 1-2-3 with AuraClens System

Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the AuraGen 1-2-3 with AuraClens system.

Device: AuraGen 1-2-3 with AuraClens system (BK190433)
Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: AuraGen 1-2-3 with AuraClens system

Active Comparator: Fat grafting with the Revolve System

Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the Revolve System.

Device: Revolve System (K120902)
Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: Revolve System

Outcome Measures

Primary Outcome Measures

  1. Fat volume retention at 3 months post-op [3 months post-op]

    Measurement of volume of fat graft at 3 months post-op, using 3D photography

  2. Fat volume retention at 6 months post-op [6 months post-op]

    Measurement of volume of fat graft at 6 months post-op, using 3D photography

  3. Fat volume retention at 12 months post-op [12 months post-op]

    Measurement of volume of fat graft at 6 months post-op, using 3D photography

Secondary Outcome Measures

  1. Patient Satisfaction [3 months post-op]

    Breast-Q - Augmentation Survey

  2. Patient Satisfaction [6 months post-op]

    Breast-Q - Augmentation Survey

  3. Patient Satisfaction [12 months post-op]

    Breast-Q - Augmentation Survey

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Female patients > 18 years and < 65 years of age

  • Patients undergoing an aesthetic fat grafting procedure to the breast (breast augmentation) without a breast implant.

  • Patients must be able to provide written informed consent, understand and be willing to comply with study-related procedures and follow-up visits.

  • Patients must be non-smokers.

  • Patients with available/adequate harvest sites for fat grafting.

  • Anticipated harvested fat volume between 400 and 1400 cc

  • Anticipated fat injection volume 150-350 cc per breast

  • Patients must agree to maintain their weight (i.e. within 5%) by not making any major changes in their diet or lifestyle during the study.

Exclusion Criteria:
  • Skin rash in the treatment area.

  • Patients who smoke or use nicotine products.

  • Patients with bleeding disorders or currently taking anticoagulants.

  • Patients with a history of trauma or surgery to the treatment area.

  • Patients with a history of breast cancer.

  • Active, chronic, or recurrent infection.

  • Compromised immune system (e.g. diabetes).

  • Hypersensitivity to analgesic agents.

  • Co-morbid conditions that could limit their ability to participate in the study or to comply with follow-up requirements.

  • Untreated drug and/or alcohol abuse.

  • Pregnant or breastfeeding.

  • Any issue that, at the discretion of the investigator, would contraindicate the patient's participation.

  • Patients who do not wish to have the study area (breast) photographed

NOTE Please note that there is no remuneration for participation in this study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Back Bay Plastic Surgery Boston Massachusetts United States 02116

Sponsors and Collaborators

  • AuraGen Aesthetics LLC

Investigators

  • Principal Investigator: Daniel A Del Vecchio, MD, Back Bay Plastic Surgery

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
AuraGen Aesthetics LLC
ClinicalTrials.gov Identifier:
NCT04906811
Other Study ID Numbers:
  • AUGCS001
First Posted:
May 28, 2021
Last Update Posted:
Jun 30, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No

Study Results

No Results Posted as of Jun 30, 2021